Three crucial issues will determine whether our pp
Post# of 30028
Posted On: 11/21/2014 7:28:30 PM
Three crucial issues will determine whether our pps will rise or not:
1) Whether our patent for recombinant MANF is shown to be successful in treating eye disorders, or whether there are delivery issues. (Dr. Urano has an article coming out on Monday)
2) Whether Jason's 1 million Lympro revenue estimate was just a wild conservative guess on his part, or whether it is fairly accurate.
3) How will we pay for the purchase of ESS and the Eltoprazine trial? If some partnership happens that gives us up front money, then we move up. If these purchases and trials will all be paid for with dilution.....then that means we will not move above .10 cents for the foreseeable future.
I think all shareholders thought the purchase of ESS sounded good....down the road a couple years. But I hope Gerald wasn't counting on it's announcement to move up our stock price. Only promising revenue from Lympro this next year (15 to 40 million) or a partnership with up front money will get us above .20 cents to up list. If the Lympro spec & sens numbers are above 90% in December, but Gerald doesn't dispel Jason's 1 million revenue estimate, the pps won't rise IMHO.
1) Whether our patent for recombinant MANF is shown to be successful in treating eye disorders, or whether there are delivery issues. (Dr. Urano has an article coming out on Monday)
2) Whether Jason's 1 million Lympro revenue estimate was just a wild conservative guess on his part, or whether it is fairly accurate.
3) How will we pay for the purchase of ESS and the Eltoprazine trial? If some partnership happens that gives us up front money, then we move up. If these purchases and trials will all be paid for with dilution.....then that means we will not move above .10 cents for the foreseeable future.
I think all shareholders thought the purchase of ESS sounded good....down the road a couple years. But I hope Gerald wasn't counting on it's announcement to move up our stock price. Only promising revenue from Lympro this next year (15 to 40 million) or a partnership with up front money will get us above .20 cents to up list. If the Lympro spec & sens numbers are above 90% in December, but Gerald doesn't dispel Jason's 1 million revenue estimate, the pps won't rise IMHO.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼